Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland

Maria Trottmann; Eva Blozik; Marcel Hilbig; Mark Pletscher; Niklaus Meier

doi:10.57187/s.3958

Author reply to technical comment

Vol. 154 No. 10 (2024)

Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland

Maria Trottmann
Eva Blozik
Marcel Hilbig
Mark Pletscher
Niklaus Meier

Cite this as:: Swiss Med Wkly. 2024;154:3958
Published: 03.10.2024

Summary

No abstract available.

References

Arber C, Baerlocher G, Chalandon Y, Daskalakis Michael, Duchosal M, Fehr M, et al. Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2024;154:3704.doi: https://doi.org/https://doi.org/10.57187/s.3704
Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html
Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 26. April 2022;6(8):2536–47.
Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J. Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021 Jun;38(6):3266–80. doi: https://doi.org/10.1007/s12325-021-01756-0

How to Cite

1.

Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland. Swiss Med Wkly [Internet]. 2024 Oct. 3 [cited 2025 Oct. 13];154(10):3958. Available from: https://smw.ch/index.php/smw/article/view/3958

Share

This work is licensed under a Creative Commons Attribution 4.0 International License.

DOI:: https://doi.org/10.57187/s.3958

[1] Arber C, Baerlocher G, Chalandon Y, Daskalakis Michael, Duchosal M, Fehr M, et al. Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2024;154:3704.doi: https://doi.org/https://doi.org/10.57187/s.3704

[2] Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html

[3] Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 26. April 2022;6(8):2536–47.

[4] Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J. Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021 Jun;38(6):3266–80. doi: https://doi.org/10.1007/s12325-021-01756-0